Phase I/II Cervical + Chemotherapy

Authors: de Wit R, van der Zee J, van der Burg ME, Kruit WH, Logmans A, van Rhoon GC, Verweij J.
Publication: Br J Cancer. 1999 Jul;80(9):1387-91.

ABSTRACT:
We investigated the feasibility and the anti-tumour activity of weekly cisplatin and the simultaneous application of local hyperthermia in patients with a pelvic recurrence of cervical cancer in previously irradiated area. Dose levels of cisplatin 60 mg m(-2), 70 mg m(-2) and 80 mg m(-2) were studied.

Phase I/II Deep Tumor + Radiotherapy

Authors: Myerson RJ, Scott CB, Emami B, Sapozink MD, Samulski TV.
Publication: Int J Hyperthermia. 1996 Jul-Aug;12(4):449-59.

PURPOSE:
The purpose of this paper is to evaluate the safety and efficacy of deep hyperthermia in conjunction with radiation therapy.

Phase I/II Soft Tissue Sarcoma + Radiotherapy

Authors: Scully SP, Oleson JR, Leopold KA, Samulski TV, Dodge R, Harrelson JM.
Publication: J Surg Oncol. 1994 Nov;57(3):143-51.

PURPOSE:
In the treatment of soft tissue sarcomas, hyperthermia has been demonstrated to enhance tumor necrosis from radiation therapy. The current study reports the clinical course of patients treated with this neoadjuvant therapy regimen.

Phase I/II Cervical + Radiotherapy + Chemotherapy

Authors: Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der Velden J, Burger C, van der Wilt CL, Dahl O, Prosnitz LR, van der Zee J.
Publication: Cancer. 2005 Aug 15;104(4):763-70.

BACKGROUND:
Patients with advanced cervical carcinoma are treated routinely with radiotherapy and cisplatin-containing chemotherapy. It has been shown that hyperthermia can improve the results of both radiotherapy and cisplatin. In the current study, the feasibility and efficacy of the combination of all three modalities was studied in previously untreated patients with cervical carcinoma.

Phase I/II Pediatric Germ Cell + Chemotherapy

Authors: Wessalowski R, Kruck H, Pape H, Kahn T, Willers R, Göbel U.
Publication: Cancer. 1998 Feb 15;82(4):793-800.

PURPOSE:
Extracranial nontesticular germ cell tumors (GCTs) are rare malignancies in children and adolescents. Cisplatin-containing regimens and complete tumor resection are important determinants for a favorable outcome; however, patients with recurrent tumors that cannot be eradicated by surgical procedures and chemotherapy have a poor prognosis. Noninvasive electromagnetic technologies for superficial and regional deep hyperthermia (RHT) are under investigation to enhance local tumor control in various malignancies. The objectives of this Phase I/II study were to examine 1) whether RHT can be used in combination with platinum-based chemotherapy with acceptable toxicity in children and adolescents and 2) whether this combined regimen can induce objective tumor response in patients with malignant nontesticular GCT that persisted or recurred locoregionally after validated, intensive, cisplatin-based chemotherapy +/- surgery as unsuccessful first-line treatment.

Phase I/II Soft Tissue Sarcoma + Chemotherapy

Authors: Fiegl M, Schlemmer M, Wendtner CM, Abdel-Rahman S, Fahn W, Issels RD.
Publication: Int J Hyperthermia. 2004 Sep;20(6):661-70.

PURPOSE:
To evaluate the efficacy and safety of the combination of ICE (ifosfamide 1.5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy.

Phase I/II Cervical + Radiotherapy + Chemotherapy

Authors: Westermann A, Mella O, Van Der Zee J, Jones EL, Van Der Steen-Banasik E, Koper P, Uitterhoeve AL, De Wit R, Van Der Velden J, Burger C, Schem BC, Van Der Wilt C, Dahl O, Prosnitz LR, Van Tinteren H.
Publication: Int J Hyperthermia. 2012;28(6):549-53. doi: 10.3109/02656736.2012.673047. Epub 2012 Jul 13.

BACKGROUND:
Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy. Hyperthermia has been shown to improve the results of both radiotherapy and cisplatin. The feasibility of the combination of all three modalities was demonstrated and reported in a study of 68 previously untreated cervical cancer patients in 2005. Long-term follow-up is presented here.

Phase I/II Deep Tumors + Radiotherapy

Authors: Myerson RJ, Leybovich L, Emami B, Grigsby PW, Straube W, Von Gerichten D.
Publication: Int J Hyperthermia. 1991 Nov-Dec;7(6):937-51.

PURPOSE:
The BSD 2000 system is an array of microwave antennas operating in the 60-120 MHz range. It is a four-quadrant regional hyperthermia device with phase control permitting the operator to choose the point of constructive interference. A computer preplanning system is provided.

Phase I/II Ovarian + Chemotherapy

Authors: Alvarez Secord A, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW.
Publication: Int J Hyperthermia. 2005 Jun;21(4):333-47.

OBJECTIVE:
A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasation into tumour xenografts resulting in enhanced cytotoxic effects.

Phase I/II Ovarian + Chemotherapy

Authors: Hahn CA, Jones EL, Blivin JL, Sanders LL, Yu D, Dewhirst MW, Secord AA, Prosnitz LR.
Publication: Int J Hyperthermia. 2005 Jun;21(4):349-57.

PURPOSE:
Prospective assessment of quality of life (QoL) in patients with refractory, residual or recurrent ovarian cancer receiving whole abdomen hyperthermia and intravenous liposomal doxorubicin chemotherapy.

Phase I/II Ovarian + Chemotherapy

Authors: Fotopoulou C, Cho CH, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, Sehouli J.
Publication: Int J Hyperthermia. 2010;26(2):118-26. doi: 10.3109/02656730903369200.

PURPOSE:
Due to the poor prognosis of patients with ovarian cancer relapse (OCR), newer strategies are warranted to improve the therapeutic index. We performed a prospective phase I/II-study of regional abdominal hyperthermia (RHT) combined with systemic chemotherapy in OCR patients in order to evaluate outcome, efficacy and tolerance.

Phase I/II Prostate + Radiotherapy

Authors: Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, Felix R, Wust P.
Publication: Strahlenther Onkol. 2005 Jan;181(1):35-41.

PURPOSE:
Since long-term results of the standard treatment of locally advanced or recurrent prostatic carcinoma are unsatisfactory, the role for additional regional hyperthermia was evaluated in a phase I/II study.

Phase I/II Prostate + Radiotherapy

Authors: Kaplan I, Kapp DS, Bagshaw MA.
Publication: Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):551-4.

ABSTRACT:
At Stanford, six patients underwent a course of external radiotherapy after local recurrence following 125-iodine implantation.

Phase I/II Soft Tissue Sarcoma + Radiotherapy

Authors: Prosnitz LR, Maguire P, Anderson JM, Scully SP, Harrelson JM, Jones EL, Dewhirst M, Samulski TV, Powers BE, Rosner GL, Dodge RK, Layfield L, Clough R, Brizel DM.
Publication: Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):941-9.

PURPOSE:
To explore the use of a novel program of preoperative radiation and hyperthermia in the management of high-grade soft tissue sarcomas (STS).